Study Design We identified 1 double-blinded RCT (SUSTAIN FORTE) published in 2021
Where you inject your GLP-1 agonist affects how quickly the drug reaches peak plasma levels, which in turn affects the timing of both therapeutic effects and side effects
The amount of bacteriostatic water you add determines the concentration of your solution, which determines how many units you draw for each dose, which determines whether your results match the research or fall flat
Similarly, clinicians, policy-makers, and people with obesity may find the mean weight loss of a treatment of little practical or planning value, while the proportions of people achieving categorical weight loss of 5, 10, and 15% might be more relevant to inform real-world clinical practice
This difference in average outcomes is something your provider will weigh alongside your personal health history and how well you are tolerating the treatment